JP2025511135A5 - - Google Patents

Info

Publication number
JP2025511135A5
JP2025511135A5 JP2024557935A JP2024557935A JP2025511135A5 JP 2025511135 A5 JP2025511135 A5 JP 2025511135A5 JP 2024557935 A JP2024557935 A JP 2024557935A JP 2024557935 A JP2024557935 A JP 2024557935A JP 2025511135 A5 JP2025511135 A5 JP 2025511135A5
Authority
JP
Japan
Prior art keywords
seq
bispecific antibody
sequence shown
domain
binding domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024557935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511135A (ja
JP7871988B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/016963 external-priority patent/WO2023192514A1/en
Publication of JP2025511135A publication Critical patent/JP2025511135A/ja
Publication of JP2025511135A5 publication Critical patent/JP2025511135A5/ja
Application granted granted Critical
Publication of JP7871988B2 publication Critical patent/JP7871988B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024557935A 2022-03-30 2023-03-30 Nrp1結合ドメインを含む二重特異性抗体およびその使用方法 Active JP7871988B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263325312P 2022-03-30 2022-03-30
US202263325317P 2022-03-30 2022-03-30
US63/325,312 2022-03-30
US63/325,317 2022-03-30
PCT/US2023/016963 WO2023192514A1 (en) 2022-03-30 2023-03-30 Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026080898A Division JP2026133506A (ja) 2022-03-30 2026-05-13 Nrp1結合ドメインを含む二重特異性抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2025511135A JP2025511135A (ja) 2025-04-15
JP2025511135A5 true JP2025511135A5 (cg-RX-API-DMAC7.html) 2025-11-04
JP7871988B2 JP7871988B2 (ja) 2026-06-09

Family

ID=86184900

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024557935A Active JP7871988B2 (ja) 2022-03-30 2023-03-30 Nrp1結合ドメインを含む二重特異性抗体およびその使用方法

Country Status (13)

Country Link
US (1) US12692315B2 (cg-RX-API-DMAC7.html)
EP (1) EP4499696A1 (cg-RX-API-DMAC7.html)
JP (1) JP7871988B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240163751A (cg-RX-API-DMAC7.html)
CN (1) CN119403831A (cg-RX-API-DMAC7.html)
AU (1) AU2023245728A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255754A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002899A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024014799A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240462A (cg-RX-API-DMAC7.html)
IL (1) IL315960A (cg-RX-API-DMAC7.html)
MX (1) MX2024011978A (cg-RX-API-DMAC7.html)
WO (1) WO2023192514A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315960A (en) 2022-03-30 2024-11-01 Pinetree Therapeutics Inc Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
AU2023317484A1 (en) * 2022-07-30 2025-03-13 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradaton and methods of use thereof
IL320410A (en) * 2022-11-07 2025-06-01 Pinetree Therapeutics Inc Combination therapy involving bispecific antibodies containing an NRP1 binding domain

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
US6302874B1 (en) 1998-07-13 2001-10-16 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗her2抗体改変体
ME01803B (me) 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
GB0503546D0 (en) 2005-02-21 2005-03-30 Hellenic Pasteur Inst Antibody
CA2628253A1 (en) 2005-11-03 2007-08-30 Genentech, Inc. Therapeutic anti-her2 antibody fusion polypeptides
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
US20100143340A1 (en) 2006-12-13 2010-06-10 Schering Corporation Methods and compositions for treating cancer
PL2155788T3 (pl) * 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
US20140112911A9 (en) 2008-12-02 2014-04-24 Liliane Goetsch Novel anti-cmet antibody
WO2010064089A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Novel anti-cmet antibody
WO2010099186A1 (en) 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Her2 antibody compositions
EP2287197A1 (en) 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
WO2011057064A1 (en) 2009-11-05 2011-05-12 Brian Long Igf1r inhibitor based treatment of prostate cancer
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
EP3904391B1 (en) 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
WO2011143408A1 (en) 2010-05-13 2011-11-17 Genentech, Inc. Use of neuropilin-1 antagonists for the treatment of cancer
JP5908972B2 (ja) 2011-04-07 2016-04-26 アムジエン・インコーポレーテツド 新規な抗原結合タンパク質
AU2012255920A1 (en) 2011-05-18 2013-11-07 Merck Sharp & Dohme Corp. Therapeutic anti-IGF1R combinations
CN102492039B (zh) 2011-11-21 2015-03-11 无锡天演生物技术有限公司 全人源抗人her2单抗
EP2863947B1 (en) 2012-06-21 2018-03-07 Sorrento Therapeutics, Inc. Antigen binding proteins that bind igf1r
WO2014189303A1 (ko) 2013-05-23 2014-11-27 아주대학교산학협력단 뉴로필린에 특이적인 종양 침투성 펩타이드 및 이 펩타이드가 융합된 융합 단백질
JP6541237B2 (ja) 2014-03-06 2019-07-10 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子1受容体特異的抗体及びそれらの使用
EP3114142B1 (en) 2014-03-06 2019-06-05 National Research Council of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
US9975960B2 (en) 2014-05-09 2018-05-22 Samsung Electronics Co., Ltd. Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
KR101551306B1 (ko) 2015-03-23 2015-09-09 아주대학교산학협력단 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도
ES3043088T3 (en) 2015-06-17 2025-11-24 Hoffmann La Roche Anti-her2 antibodies and methods of use
WO2017171373A2 (ko) * 2016-03-29 2017-10-05 아주대학교산학협력단 Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
KR102048474B1 (ko) 2016-03-29 2019-11-26 아주대학교산학협력단 Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
KR101985299B1 (ko) 2016-06-03 2019-09-03 삼성전자주식회사 항-c-Met/항-Nrp1 이중 특이 항체
US10167342B2 (en) 2016-08-29 2019-01-01 Fazel Shokri Production of hersintuzumab: a new humanized antibody against HER2 for cancer treatment
LT3512882T (lt) 2016-09-14 2021-06-25 Merck Patent Gmbh Anti-c-met antikūnai ir jų antikūno-vaisto konjugatai, skirti efektyviam naviko slopinimui
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
EP3615571A1 (en) * 2017-04-24 2020-03-04 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
EP3680250A4 (en) 2017-09-08 2021-07-14 Ajou University Industry-Academic Cooperation Foundation COMPOSITION LIMITING THE ACTIVITY OF A REGULATING T LYMPHOCYTE, INCLUDING A PEPTIDIC BINDING SPECIFIC TO NEUROPILIN 1 (NRP1)
KR102054389B1 (ko) 2017-10-26 2019-12-11 아주대학교산학협력단 뉴로필린1에 특이적으로 결합하는 Non-CendR 펩타이드, 상기 펩타이드가 융합된 융합 단백질 및 이의 용도
KR102956998B1 (ko) 2018-07-31 2026-04-27 도꾜 다이가꾸 새로운 결합 특이성을 항체에 부여하는 초범용법
EP3867273A1 (en) 2018-10-19 2021-08-25 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of squamous cell cancers
JP2022510218A (ja) 2018-11-30 2022-01-26 メモリアル スローン ケタリング キャンサー センター ヘテロ二量体四価特異性抗体およびこれらの使用
MX2021008121A (es) 2019-01-03 2021-12-10 Inst Nat Sante Rech Med Metodos y composiciones farmaceuticas para mejorar las respuestas inmunitarias dependientes de celulas t cd8+ en sujetos que sufren de cancer.
WO2022026943A2 (en) 2020-07-31 2022-02-03 Pinetree Therapeutics, Inc. Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infections
IL315960A (en) 2022-03-30 2024-11-01 Pinetree Therapeutics Inc Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
IL320410A (en) 2022-11-07 2025-06-01 Pinetree Therapeutics Inc Combination therapy involving bispecific antibodies containing an NRP1 binding domain
EP4754135A1 (en) 2023-07-28 2026-06-10 Pinetree Therapeutics, Inc. Non-receptor tyrosine kinase compositions for targeted lysosomal degradation and methods of use thereof

Similar Documents

Publication Publication Date Title
JP7854016B2 (ja) 腫瘍治療薬及びその応用
JP2025111463A5 (cg-RX-API-DMAC7.html)
CN107849148B (zh) 三特异性结合蛋白质及使用方法
JP2024531409A5 (cg-RX-API-DMAC7.html)
CN116396386A (zh) Cd3抗体及其药物用途
TW201026325A (en) Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment
WO2022042719A1 (zh) 抗vegf-抗pd-l1双特异性抗体、其药物组合物及用途
CN114423790B (zh) 靶向caix抗原的纳米抗体及其应用
WO2023174396A1 (zh) 一种新型免疫调节剂的开发和应用
JP7533897B2 (ja) 融合タンパク質およびその使用
JP2021510736A5 (cg-RX-API-DMAC7.html)
JP2025038088A5 (cg-RX-API-DMAC7.html)
CN112105391B (zh) 抗-bcma抗体及其用途
IL315960A (en) Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
JP2024538148A5 (cg-RX-API-DMAC7.html)
JP2024024114A5 (cg-RX-API-DMAC7.html)
JP2023544143A5 (cg-RX-API-DMAC7.html)
CN114685666B (zh) 抗间皮素纳米抗体及其应用
JP2023506834A5 (cg-RX-API-DMAC7.html)
JP2023504733A (ja) 抗clec-1a抗体及びその抗原結合性断片
WO2022228424A1 (zh) 一种抗egfr/vegf双功能融合蛋白及其用途
WO2023142297A1 (zh) Muc1结合分子及其应用
JP2025524306A (ja) Itga2を標的とする抗体及びそれを含む抗体薬物複合体
CN114829405A (zh) 抗bcma/抗4-1bb双特异性抗体及其用途
CN110922486A (zh) 一种分离的结合抗原psma的蛋白及其用途